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Abstract
Background: Anecdotal evidence of the involvement of alternative splicing (AS) in the regulation of protein-
protein interactions has been reported by several studies. AS events have been shown to significantly occur in
regions where a protein interaction domain or a short linear motif is present. Several AS variants show partial or
complete loss of interface residues, suggesting that AS can play a major role in the interaction regulation by
selectively targeting the protein binding sites. In the present study we performed a statistical analysis of the
alternative splicing of a non-redundant dataset of human protein-protein interfaces known at molecular level to
determine the importance of this way of modulation of protein-protein interactions through AS.
Results: Using a Cochran-Mantel-Haenszel chi-square test we demonstrated that the alternative splicing-mediated
partial removal of both heterodimeric and homodimeric binding sites occurs at lower frequencies than expected,
and this holds true even if we consider only those isoforms whose sequence is less different from that of the
canonical protein and which therefore allow to selectively regulate functional regions of the protein. On the other
hand, large removals of the binding site are not significantly prevented, possibly because they are associated to
drastic structural changes of the protein. The observed protection of the binding sites from AS is not preferentially
directed towards putative hot spot interface residues, and is widespread to all protein functional classes.
Conclusions: Our findings indicate that protein-protein binding sites are generally protected from alternative
splicing-mediated partial removals. However, some cases in which the binding site is selectively removed exist,
and here we discuss one of them.
Keywords: Alternative splicing, Protein-protein interaction, Hot spots, Protein three-dimensional structure,
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Background
Protein function is often modulated by binding with spe-
cific partners. Protein-protein interactions can be regulated
by post-translational modifications, such as phospho-
rylation [1-3], or via binding with small ligands [4,5].
Moreover many examples are known of protein-protein
interactions that are regulated via AS [6,7]. AS can modu-
late interactions by: i) removing binding sites or domains;
ii) inserting a stretch of sequence that disrupts binding; iii)
modulating the inclusion of a specific binding motif. Seve-
ral studies have attempted to assess how widespread these
forms of regulation are. The overall impact of alternative
splicing on protein-protein interaction domains was inves-
tigated in a work published in 2004 [8], which indicates
that the majority of the domains that are removed by alter-
native splicing at high frequencies are protein-protein
interaction domains. The authors analyzed 13384 protein
isoforms of 4442 genes and found that 50 protein domain
types were significantly removed by alternative splicing at
higher frequencies; this list of domain types was enriched
in domains involved in protein-protein interactions. The
effects of AS on the inclusion or exclusion of short inter-
acting modules have also been studied in a systematic way
[9]. The analysis of 1421 protein isoforms produced from
404 genes showed that regions that are alternatively spliced
are enriched in short linear motifs that are typically in-
volved in low-affinity interactions [10]. Ellis and coworkers
also found that linear motifs are enriched within tissue-
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specific alternative coding exons [11]. They employed a
splicing variant-specific form of the co-immunoprecipita-
tion assay to demonstrate the extensive and tissue-specific
rewiring of protein interaction networks mediated by the
inclusion of specific alternative exons. Another way, though
less commonly observed, through which protein-protein
interactions can be modulated by alternative splicing is the
selective (complete or partial) removal of the region that
physically interacts with the partner—the binding site or
interface, which may be part of a domain or not, and which
often does not coincide exactly with a linear motif [12-16].
In this work we investigated whether the regulation of
protein-protein interactions through AS-mediated remo-
val/substitution of the binding site is limited to specific
examples or conversely represents a widespread pheno-
menon. To this end we evaluated in a systematic way
the extent of the overlap between alternatively spliced
regions and binding residues in human proteins. In
principle the overlap could be significantly higher (i.e.
AS preferentially targets protein-protein interfaces),
lower (interfaces are “protected” from AS), or not sig-
nificantly different from expectation.
Similar studies have been conducted in the past, but
we argue that a systematic statistical analysis is still
lacking. A work published in 2004 [17] showed that
protein-protein interface residues, extracted from com-
plexes of known structure, are not preferentially spliced
nor protected from AS. However, this work was based
on too small a number of cases to draw general conclu-
sions (16 proteins involved in heterodimeric interactions
and 5 involved in homodimeric interactions). In 2006
Yura and coworkers analyzed 242 alternatively spliced
regions covering less than 100 amino acids and found
that in 57% of cases they partially or totally co-localize
with functional sites of human proteins - defined as
protein-protein, protein-ligand and protein-DNA/RNA
binding sites [18]. However, the authors did not try to
assess the statistical significance of this result.
Here we perform a systematic study of the relationship
between AS and protein-protein interfaces in the human
proteome. First we created two data sets, composed of
proteins whose genes undergo alternative splicing and
that are involved in heterodimeric (431 binding sites) or
homodimeric (763 binding sites) interactions, as defined
from complexes of known structure. We then demon-
strated that, for both classes of interaction, the removal
of a portion of the interacting site occurs less frequently
than expected under a random model. This tendency is
maintained even if we filter out isoforms that are
extremely different from the canonical one and that are
likely to produce drastic structural changes. We also
found that hot spot residues, i.e. the ones that contribute
most to the binding energy [19,20], do not behave diffe-
rently from the rest of the interface. Finally, we found
that the relationship between AS and interface residues
does not depend on the functional class of the protein.
Results and discussion
Data sets creation
We first created a dataset of human protein-protein
interfaces, starting from complexes of known structure
in the Protein Data Bank (PDB) [21]. Using a simple dis-
tance criterion to identify interface residues, we obtained
a set of 2763 heterodimeric and 5846 homodimeric
interfaces in structures that have a good coverage of the
corresponding protein sequences. We will use the term
“semi-interface” to refer to a group of interface residues
belonging to one of the interacting chains. We then
selected all the proteins that could be mapped to a
transcript with at least one alternative splicing isoform,
thus retaining 2757 heterodimeric semi-interfaces and
4356 homodimeric interfaces. These data sets are redun-
dant because of two main reasons: i) the same interaction
can be represented multiple times, not only in different
PDB structures but also within the same complex, e.g. in
the case of a homomultimer having more than two chains;
ii) similar (paralogous) proteins can interact with the same
partner by using homologous residues [22]. In the latter
case, even though the pattern of alternative splicing
rapidly diverges after gene duplication [23], the way in
which alternative splicing acts on related interfaces could
remain similar, thus introducing some bias in the statis-
tical analysis. To remove redundancy we selected a single
representative for each group of interfaces (or semi-
interfaces in the case of heterodimers) that are similar and
belong to similar or identical proteins. We thus obtained a
non-redundant data set composed of 431 heterodimeric
semi-interfaces and 763 homodimeric interfaces. The
heterodimeric semi-interfaces we found are mapped to
305 distinct UniProt [24] entries, while the homodimeric
interfaces to 520 Uniprot entries. A total of 754 and 1304
distinct alternative isoforms were found for the former
and the latter class of proteins, respectively. The Uniprot
entries were used as reference isoforms, on which the AS
changes observed in the alternative isoforms were
mapped. Additional file 1 contains the list of proteins
involved in heterodimeric interactions, together with the
alternative splicing isoforms and the number of interface
residues they remove, while the Additional file 2 contains
the information about the homodimeric interactions.
Protein-protein interfaces are protected from alternative
splicing
We sought to determine whether the removal of protein-
protein interfaces via alternative splicing occurs at higher
or lower frequencies compared to what happens under a
random model of splicing. To do this, we followed two
alternative approaches, evaluating the splicing of the
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binding site in each isoform separately (single-isoform
test) or in each group of isoforms from the same gene
(all-isoforms test). Due to the different nature of the
interaction, these tests were performed on heterodimeric
semi-interfaces and homodimeric interfaces separately.
Indeed, in the first case the alternative splicing of a gene
can act only on a single semi-interface, while in the latter
there are two semi-interfaces, which differ by varying
degrees, that can be spliced away. In the single-isoform
test we asked whether the presence or absence of the
interface in a specific isoform can be attributed to chance,
taking into account the splicing pattern. If this hypothesis
is rejected, one can argue that the inclusion or removal of
the interacting region might be the result of some
evolutionary pressure. To perform this test, we conside-
red every heterodimeric semi-interface/isoform pair and
assessed whether the isoform contains the interface region
or not. An heterodimeric semi-interface is regarded as
removed if the isoform does not contain at least a certain
fraction of its residues. Since it is not easy to determine
what is the minimum percentage of interface residues that
must be spliced away in order to abolish the interaction,
we repeated the test using different values for this
interface-removal threshold. In order to derive a random
background against which to evaluate the significance of
the observed removal rate, we created 1000 decoys for
each isoform (used as controls for the test), using a pro-
cedure that takes into account the specific splicing pattern
of the isoform (see Methods for details). We then
performed a Cochran-Mantel-Haenszel (CMH) chi-square
test [25] to determine whether the frequency at which
alternative splicing removes the interfaces is significantly
different from that obtained using the decoys. The results
of this test performed on heterodimeric semi-interfaces,
using different interface-removal thresholds, are summa-
rized in Figure 1A. The percentage of interface/isoform
pairs in which the interface is removed via alternative
splicing is quite high (e.g. in about 28% of the cases 30%
or more of the interface is removed), but it is still signifi-
cantly lower than what is observed under a random model
Figure 1 Alternative splicing-mediated partial removal of protein interfaces is less frequent than expected. The results obtained for
the single-isoform (A for heterodimeric interactions and B for homodimeric interactions) and for the all-isoforms tests (C for heterodimeric
interactions and D for homodimeric interactions) are summarized here. For each value of the interface-removal threshold, the frequency at
which an interface is removed by real splicing (red line) and by randomized splicing (blue line) is reported, along with the p-value of the test
(green is significant).
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of splicing. This difference decreases as the threshold values
increases, to become almost zero when the threshold value
is equal to 100%. The differences observed using threshold
values <= 80% are significant (p-value < 0.05), and the
significance is higher for lower thresholds. These results
suggest that alternative splicing tends to avoid partial
removals of heterodimeric interaction sites, while being
quite indifferent to large excisions - possibly because they
occur along with major rearrangements of the protein, in
which cases there might be no pressure in maintaining the
interaction. The single-isoform test for homodimeric inter-
faces was performed in a similar way, the only difference
being that in this case an interface is considered removed if
at least one of the two semi-interfaces lacks a certain
percentage of its residues or more. As shown in Figure 1B,
also in this case partial removals of the interface are signi-
ficantly prevented, though the significance is lost at a lower
threshold compared to heterodimers. Furthermore, really
large interface excisions occur more frequently, but not in a
significant way.
Using the single-isoform test, we can analyse the
selective pressure towards interface retention for each
individual isoform. However we underestimate all the
cases in which the abolishment of the interaction occurs
only in one or few isoforms among all those produced
by the same gene, while the others are still able to inter-
act, or at least they maintain the interface residues; for
example, if a gene has 5 isoforms, but only one lacks the
binding site, the signal coming from that lone isoform is
masked by the other four. Moreover, different isoforms
from the same gene can depend on the same splice junc-
tions, hence the interacting proteins with the largest
number of splicing isoforms contribute the most to the
final result, not only because they are associated to a
higher number of contingency tables in the CMH test
(see Methods for details), but also because the splicing
patterns of their isoforms are somewhat dependent. For
these reasons, we performed another test, called all-
isoforms test, whose purpose was to determine how
likely is for an interface to be selectively removed in at
least one isoform. In this case, for each interacting pro-
tein we created 1000 random controls, each consisting
of a group of decoy isoforms all derived from the real
isoforms of its gene. A CMH test was employed to
determine whether the frequency at which a binding site
is removed in at least one isoform is significantly different
from that obtained under this random model of AS. The
test showed a significant protection form partial removals
both for heterodimeric (Figure 1C) and homodimeric
(Figure 1D) interfaces, even if homodimeric interfaces
appear to tolerate larger removals compared to hetero-
dimeric ones (again, the frequency at which they undergo
large removals is higher than that of the background, but
not in a statistically significant way). Ultimately, the
possibility of regulating protein-protein interactions
through the production of an isoform which specifically
lacks part of the interface region is realized less than
expected; the excision of an interface is not so uncommon
per se, since, for example, about 42% of the heterodimeric
semi-interfaces undergo a removal of 30% or more of their
residues in at least one isoform, but there is a general ten-
dency towards the protection of the binding sites from AS.
Interface protection is maintained in similar isoforms
The set of isoforms we used includes a number of tran-
scripts that are markedly different from the canonical
isoform, i.e. the isoform that corresponds to the PDB
chain. These conspicuous changes are likely to result in
the disruption of the 3D structure or in the production
of a new structural conformation [26]. Therefore, even if
the interface region is not removed, it is reasonable to
assume that these isoforms would hardly maintain a
conformation that allows the interaction. Hence, we
repeated the previously described statistical analyses
including only isoforms that maintain most of the
sequence of the canonical protein. We used a variable
threshold for this coverage value (from 0 to 100% in incre-
ments of 10%). Both for heterodimeric and homodimeric
interfaces, the results of the two tests showed again a
significant protection from partial removals, and this was
true irrespective of the threshold values (these results are
shown in the Additional file 3). The tendency for alterna-
tive splicing to avoid interfaces is thus confirmed in those
isoforms that are more likely to be involved in a fine regu-
lation of the interaction.
Hot spots are not protected more than other interface
residues
Since some interface residues are more important than
others for the interaction to be established, we sought to
determine the behaviour of alternative splicing towards
these protein-protein interaction hot spots. Again, we
employed the single-isoform and the all-isoforms tests,
this time considering only those heterodimeric interface
residues that were predicted to be hot spots (15 inter-
faces do not contain any hot spot, and were not included
in the analysis). The results are very similar to those
obtained using all the interface residues (Additional file 4).
However, it was necessary to establish whether hot spots
are more protected than other interface residues or not.
To do so, we tested the null hypothesis that, given a
heterodimeric semi-interface/isoform pair, the splicing of
an interface residue is independent of whether it is a hot
spot or not—again, this was done by using a CMH test.
Hence, although it has been shown that hot spots are
often spatially arranged in clusters called “hot regions”
[27], and a manual control of the distribution of the hot
spots on the sequence revealed that they tend to form
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clusters also in the primary structure, the protection
from partial removals of the interacting region is not
selective towards these most important residues. Pos-
sibly this occurs because any rearrangement of the
interacting site is likely to have some influence on the
interaction or, more in general, on the functionality of
the protein.
Functional significance of interface protection/removal
selectivity
Using the number of random controls that removes an
interface, it is possible to quantify how selectively
targeted is the removal or the protection of the interface
residues (see Methods for details). We selected proteins
in which removal/protection of the binding site is more
specific, and determined whether these two classes of
proteins differ by properties that can be described using
Gene Ontology (GO) [28] terms. To this end we eva-
luated the enrichment of GO terms in all the three main
ontologies (“Molecular Function”, “Biological Process”
and “Cellular Component”) for both classes of proteins.
No significant enrichments were observed both for the
heterodimeric and the homodimeric interactions, sug-
gesting that the protection of the interface is a widespread
phenomenon among proteins with different characteristics
and that the selective removal of the interface is not pre-
ferentially restricted to a specific group of proteins sharing
the same function or localization.
Though the results of this work suggest that interfaces
are protected from AS, there are some cases in which
the alternative splicing of the pre-mRNA is focused on
the interacting region, as reported in Additional file 5
(heterodimers) and 6 (homodimers). We searched lite-
rature to investigate some of these cases, but we did not
find any example in which the involved isoform has been
characterized as non-interacting. However, we discovered
a potential example of this regulation, involving the inter-
action between Cullin 4A (CUL4A) and DNA damage-
binding protein 1 (DDB1). Together with ROC1, which
interacts with CUL4A, these proteins form a complex
(PDB: 2hye [29]), which acts as an E3 ubiquitin ligase that,
among other things, participates in the degradation of
DNA damage-response proteins [30-34]. The N-terminal
region of CUL4A is bound to a beta-propeller domain of
DDB1. The CUL4A pre-mRNA undergoes alternative spli-
cing: the protein observed in the crystal can be mapped to
the Ensembl [35] ENST00000375440 (the “canonical”
transcript), while three other full-length coding transcripts
exist, which share the same coding sequence. The only
difference between the coding sequence of the alternative
transcripts and that of the canonical one is that the former
lacks the first 100 residues of the latter. Figure 2 shows
the interaction between CUL4A and DDB1 and highlights
the region of CUL4A that is missing in the alternative
isoforms. To our knowledge, the functionality of the alter-
native isoforms has not been well characterized. However
it is quite likely that, since they lack 19 of the 30 semi-
interface residues, they are not capable of binding DDB1.
Indeed it has been reported that the deletion of the first
97 amino acids of the canonical protein completely
abolishes DDB1 binding [36]. Despite the general trend
towards protection of interfaces from AS, in this case we
observe a selective partial removal of the interface, and
this is likely to result in the production of protein isoforms
that cannot bind to a specific partner. We also inves-
tigated the tissue-specific expression patterns of the
transcripts encoding CUL4A. As shown in Figure 3, the
canonical isoform is expressed only in some tissues, while
the expression of the alternative transcripts taken together
covers all the tissues and is higher than that of the canon-
ical transcript in the tissues where it is present. Hence, in
addition to other regulatory processes that might influ-
ence the interaction, alternative splicing seems to provide
a mechanism through which the association of CUL4A
with DDB1 is only possible in a specific subset of human
tissues.
Conclusions
The present study demonstrates that the removal of
protein-protein interfaces by AS is generally avoided in
the human proteome, and this holds true for both
heterodimeric and homodimeric interactions. These results
are not in disagreement with previous works demonstrat-
ing that protein-protein interaction domains and protein
interaction-associated linear motifs are significantly found
in alternatively spliced regions [8,9,11]. Indeed, in the
analysed dataset, only ~37% of the heterodimeric semi-
interfaces and only ~45% of the homodimeric interfaces
we analysed are fully included in a PFAM [37] domain.
Moreover, putative SliMs (i.e. short linear motifs) inter-
acting with domains are present in very low amounts in
our data set. We used the iELM web server [38,39] to
analyse our lists of heterodimeric and homodimeric
interacting protein pairs and predict SliM-mediated inter-
actions, and we found that only 6 out of 431 heterodimeric
semi-interfaces and 19 out of 763 homodimeric interfaces
contain at least one residue belonging to a putative
domain-binding SliM. We additionally verified whether the
protein interaction interfaces in our datasets overlap with
protein disordered regions, since it is known that AS
events are preferentially located in such locations [40,41]:
these regions are enriched in functional motifs [42,43] and
are more tolerant to the structural changes introduced by
AS. Since they are derived from the three-dimensional
structures of crystallized proteins, our binding sites are
almost totally localized outside disordered regions: only
16 heterodimeric semi-interfaces and 26 homodimeric in-
terfaces have 30% or more of their residues in a putative
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Figure 2 CUL4A interacting with DDB1 using its N-terminal region, which is partially removed by alternative splicing. The protein on
the right is CUL4A. The region that is missing in the alternative isoforms is colored in red. The residues of CUL4A that interact with DDB1 and
that are located in the alternatively spliced region are colored in orange, while the others in yellow. The other proteins present in the crystal are
not included.
Figure 3 CUL4A isoforms show different expression patterns. The heatmap reports the expression levels (FPKM) of the transcripts using a
color scale and grouping the expression patterns by similarity. The row referred to the canonical transcript is marked with an asterisk.
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disordered conformation (to obtain the information about
the disordered regions we extracted the consensus pre-
dictions stored in the Database of Disordered Protein
Predictions [44]). This is due to the fact that these sites
are derived from the three-dimensional structures of
crystallized proteins; furthermore, we filtered out those
crystallized dimers in which the two interacting chains
cover less than 30% of the complete protein sequence,
thereby eliminating the interactions mediated by small
peptides, which are often embedded into disordered
regions. Given all these results, it is clear that the
feasibility of an AS-mediated removal of the binding
site depends on the structural characteristics of the
interaction, since, for instance, it is easier to modulate
the inclusion of SliMs, which are often localized in
disordered regions, than it is to remove or substitute
binding sites that reside in structurally defined regions.
In any case, these considerations do not concern those
cases in which the regulation of the interaction does
not consist in a direct removal/substitution of the
region involved in the interaction (which can be a
domain, a motif or an interface), e.g. when a sequence
is inserted within a binding domain.
Our findings are confirmed even when we consider
only those alternative transcripts whose coding sequence
is only slightly different from that of the canonical
isoforms. Moreover, the protection from alternative
splicing is not limited to the interface residues that
significantly contribute to the binding free energy, thus
emphasizing the importance of maintaining the global
architecture of the binding site. This requirement seems
to be common to proteins with different properties: the
proteins in which alternative splicing selectively avoids
the binding site were not found to be prevalently asso-
ciated to any specific function, biological process or
localization. This was also observed for those proteins in
which the binding site is selectively removed in one or
more isoforms. We studied one of these cases, repre-
sented by the partial removal of the region through
which Cullin 4A interacts with DDB1, and found that
the isoforms lacking the binding site show an expres-
sion pattern that greatly differs from that of the
interacting protein. Recent works show how the tissue-
specific AS of protein-protein binding sites, especially
when disordered, has an important role in rewiring
protein-protein interaction networks in a tissue-specific
fashion [11,45]. As a further extension of our study, we
are currently analysing splicing isoform-specific expres-
sion patterns in combination with our dataset of
binding sites, which reside mostly outside disordered
regions, in order to understand how isoforms con-
taining a different portion of a structured binding site
(or lack thereof ) are used in different tissues and/or
conditions.
Methods
Identification of human protein-protein interfaces
To obtain a set of human protein-protein interfaces, we
searched for all the x-ray PDB structures containing two
or more human protein chains, thus obtaining a set of
6637 PDB structures. We retained only those chains that
could be unambiguously assigned to UniProt entries
according to SIFTS [46] (about 93% of the total). The
SIFTS resource was also used to obtain a residue-level
mapping between PDB and UniProt sequences. We
employed the HotPOINT [47] algorithm to fetch interface
residues; some of these residues were classified as hot
spots by the program, however, since the program has
been trained on a set composed of only heterodimers, we
rely only on the hot spots predicted for this kind of inter-
action. The distance threshold for the identification of the
interacting residues was set to the default value (two resi-
dues belonging to different chains are assumed to interact
if there is at least one atom from one residue that is at a
distance from any atom of the second residue at most
equal to the sum of Van der Waals radii of the two
atoms + 0.5Å). To avoid crystallographic artifacts, the
search for protein-protein interaction interfaces was
conducted only on those pairs of protein chains of the
Asymmetric Unit that were present with the same relative
orientation in at least one of the Biological Units assigned
by the authors of the structure. Among these pairs, 13136
interact with at least one pair of residues mapped on the
UniProt sequence. We took only the interfaces in which
both chains interact with at least five residues, thus
obtaining a set of 11555 dimers. Moreover, we filtered out
all the dimers in which the sequence of one or both chains
does not cover at least 30% of the corresponding UniProt
sequence.
Alternative splicing data retrieval
The genes coding for the interacting proteins were found
using Biomart [48] to mine Ensembl cross-references.
Out of 1167 distinct proteins, 1113 were unambiguously
assigned to an ENSG (i.e. an Ensembl gene). Each of them
was aligned with all the transcripts associated to the corre-
sponding gene using the Needleman-Wunsch algorithm
[49]. For 1057 proteins it was possible to find one or more
ENSTs (i.e. the Ensembl transcripts) with identical coding
sequence. The remaining proteins were associated to
the most similar transcripts, provided that there
were up to five non-contiguous gaps or substitutions
(28 proteins did not satisfy this condition). For each of
the 1085 proteins that were assigned to a transcripts,
we took all the other full-length protein-coding ENSTs
belonging to the same ENSG as alternative splicing
isoforms; those transcript that are subject to nonsense-
mediated decay according to Ensembl were not took
into consideration. This way we obtained a set of 804
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proteins whose genes encode for one or more alter-
native splicing isoforms distinct from the reference
protein sequence.
Redundancy reduction
To perform a clustering of the interfaces and to select one
representative for each interface, we first grouped together
similar proteins using the BLASTClust software [50],
which is based on BLAST [51]; two proteins were
clustered together if they had >= 30% sequence identity
over an area covering at least 90% of each sequence. The
804 proteins whose genes undergo alternative splicing
resulted divided into 723 similarity groups. For each group
of similar sequences, a multiple sequence alignment was
performed using T-coffee [52]. These alignments allowed
us to compare interfaces from proteins belonging to the
same similarity group, since each interface residue could
be mapped to the multiple alignment and identified with
its alignment column number. All the heterodimeric
semi-interfaces of proteins within the same cluster were
clustered using a hierarchical complete linkage algorithm
with distance measure 1 – O, where O is an overlap value
defined as the number of identical residue identifiers
between two semi-interfaces divided by the number of
residues of the smallest semi-interface. To obtain the
clusters, the clustering tree was cut at a height equal to
0.5: this way we grouped together semi-interfaces with
O >= 0.5. This clustering procedure was inspired by a
work from Bordner and Gorin [53]. A similar method was
used to cluster homodimeric interfaces. In this case, O is
defined as the number of identical residue identifiers
between two interfaces divided the number of residues of
the smallest interface. The numerator can have two
different values, because one of the two semi-interfaces
from one dimer can be compared with both the semi-
interfaces from the other dimer; for each pairs of inter-
faces we have chosen the combination that maximizes
the numerator.
For each cluster we elected a representative (semi-)
interface by applying these criteria:
– Choose the interface associated to the
chain that most covers the UniProt sequence
(in the case of homodimers we use the
product of the coverage of the two interacting
chains);
– If multiple interfaces meet the above criterion,
choose among them the interface found in the PDB
entry with the best resolution;
– If multiple interfaces meet the above criterion,
choose among them the interface that has the
largest number of residues;
– If multiple interfaces remain, choose among them
randomly.
Statistical tests
In all the employed variants of the statistical analysis of
AS-mediated interface removal, each isoform was des-
cribed as a two-bit string, in which to each residue of
the interacting protein we assigned value 0 if it is found
in that isoform, or 1 if it is missing. We define as
“missing stretch” every stretch of contiguous 1 charac-
ters, which is a contiguous protein region removed by
splicing events. A region between two missing stretches
will be called “non-missing stretch”, while the region
that spans from the first missing stretch to the last one
(or that coincides with the only missing stretch) will be
referred to as “variable region”. The alignment between
the transcript coding for the interacting protein and
each isoform was done using the genomic coordinates of
the coding sequences provided by Ensembl.
In the single-isoform test, each control represents a
decoy isoform. These controls were created by giving
each missing or non-missing stretch a new size (number
of residues) obtained by picking a random value from a
Poisson distribution with parameter λ equal to the real
size of that stretch and choosing randomly the starting
position of the newly formed variable region (the order
of the stretches in the variable region remains the same).
This way of creating decoys by pulsing missing and non-
missing stretches allows us to generate a large set of
different controls for each isoform without radically
changing the number, the dimension and the relative
position of the alternatively spliced regions, and as a
consequence the manner in which they can act on the
interface. Figure 4 shows an example of control creation
from an isoform with one (a) or two (b) missing
stretches. After creating 1000 controls for each isoform,
we compared the frequency at which they lack the bind-
ing site with the real frequency of AS-mediated interface
removal using a CMH test. In this test, for each (semi-)
interface/isoform pair, a 2×2 contingency table is com-
piled, which describes the variables “isoform” (real or
decoy) and “interface removal” (interface is removed or
not, at a given interface-removal threshold). Table 1 is an
example of contingency table. For each table, the absolute
value of the difference between the observed and the
expected value of one cell, and the deviation between
observed and expected values are computed. These values,
obtained from all the tables, are then combined to deter-
mine whether the two variables are dependent or not. We
employed this approach instead of using a chi-square test
with a single contingency table because in this way
controls are compared only with the isoform from which
they were derived.
In the all-isoforms test, each control consists in a
group of decoy isoforms of the interacting protein, each
one made from one of the real alternative transcripts. In
this case the overlap between missing stretches of
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different isoforms has to be maintained: this way the
extension of the regions of the interacting protein that
are alternatively spliced does not vary much, the only
source of variation being the pulsation of the missing
stretch. To create a control for a given protein, we first
divided the set of isoforms of that protein in subgroups
called “overlap groups”, such that every isoform in an
overlap group had at least one missing stretch totally or
partially overlapping with the missing stretches of one or
more isoforms belonging to the same group, but not to
other groups; each isoform with no overlapping partners
was assigned to its own single-member overlap group.
For each overlap group, an “overlapping variable region”,
ranging from the minimum starting position to the
maximum ending position among all the variable regions
of the isoforms from that group, was identified. All the
junctions between a missing and a non missing stretch
or between a missing stretch and a region outside the
overlap group were used to split the corresponding over-
lapping variable region into segments: each segment is a
Table 1 Example of a 2×2 contingency table computed
for an interface/isoform pair in the single-isoform test
Interface is removed Interface is not removed
Real isoform 1 0
Decoy isoform 225 775
In this example the (semi-)interface is removed in the real isoform and in 225
out of 1000 decoy isoforms.
Figure 4 Toy examples of control creation for a single-isoform test (A and B) and for an all-isoforms test (C). (A) The isoform of an
interacting protein for which controls are created is represented as a two-bit string, in which 0 describes a conserved position (i.e. not removed
by a splicing event) and 1 a non-conserved position. A stretch of 1s is called “missing stretch” (M.S.) and is coloured in red. In this example the
isoform has one missing stretch. Controls are created by randomly changing the number of residues (size) of the missing stretch according to a
Poisson distribution with mean equal to the real size of that stretch and randomly selecting the starting point of the stretch. (B) The isoform has
two missing stretches and the region between them is called “non-missing stretch” and is coloured in blue. The region that encompasses all the
missing and non-missing stretches is called variable region. Again, controls are created changing the size of the missing stretches, but also of the
non-missing stretches (N-M.S.) and by randomly selecting the starting point of the variable region. (C) A set of isoforms forming an overlap
group, i.e. a group in which, for each isoform, the missing stretches partially or totally overlap with those of one or more isoforms from the same
group. All the variable regions in the overlap group are fused into an “overlapping variable region” divided into segments by the junctions
between missing stretches and non-missing stretches or regions outside variable regions, represented as pipes in the figure. Each segment's size
is randomly changed according to a Poisson distribution with mean equal to the segment's size, then the starting point of the newly formed
overlapping variable region is randomly selected.
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partial or entire missing or non-missing stretch that is
shared among a specific sub-group of isoforms belong-
ing to the overlap group. For each overlap group, the
starting position and the size of every segment was
changed by sampling from a Poisson distribution as
previously described for the single-isoform test. This
process is illustrated in Figure 4C. All the newly formed
overlapping variable regions were used to create the
control decoy isoforms, assigning each varied segment
to the isoforms from which it derives, provided that:
– no pair of overlapping variable regions shows an
overlap between segments derived from a missing
stretch;
– since the previous condition favors the shortening of
the missing stretches (shorter segments are less
likely to overlap), if there are multiple overlap
groups, the total number of residues in the varied
missing exons must not be less than 90% of the total
size of the real missing exons.
1000 controls were created for each interface. Again,
we performed a CMH test, compiling for each (semi-)
interface a contingency table with variables “alternative
splicing” (real or control) and “interface removal” (more
than a certain fraction of the isoform is removed in at
least one isoform or not).
To test whether hot spots are more removed or
protected than other interface residues, a CMH test was
performed, assigning to each (semi-)interface/isoform
pair a contingency table in which the number of hot
spot and non-hot spot residues that are removed or not
were reported.
All the statistical tests were performed using R version
2.14.2 [54].
Assessment of the GO terms enrichment
For each interface-removal threshold value, we assigned
each spliced interface/isoform pair a score equal to the
fraction of the single-isoform test controls that remove
the interface, representing how much that interface is
exposed to splicing in that particular isoform. We then
selected all the proteins associated to a score lower than
0.5 (i.e. those in which the interface is selectively
removed with respect to a background of splicing in at
least one isoform). The interfaces that are not spliced in
any isoform were assigned a score equal to the fraction
of the all-isoforms test controls that remove the inter-
face, and those having a score higher than 0.5 (i.e. those
proteins whose alternative splicing selectively avoids the
binding site) were selected. We employed Gorilla [55,56]
to evaluate the GO terms enrichment for both lists of
proteins (those having selectively spliced or selectively
protected interfaces) against the proteins data set used
in the test (heterodimeric or homodimeric). The eva-
luation of the GO terms enrichment was repeated for
each value of the interface-removal threshold. Only the
GO terms for which a False Discovery Rate q-value < 0.05
was obtained were considered as significantly enriched.
Different cutoff values other than 0.5 were also tested,
obtaining similar results.
Evaluation of the expression of alternative transcripts
The tissue-specific expression of the CUL4A transcript
variants was retrieved from DBATE (Bianchi et al., sub-
mitted; URL: http://bioinformatica.uniroma2.it/DBATE/),
an online database of alternative transcripts expression
that was developed in our laboratory. This database was
created processing thirteen RNA-seq panels from human
tissues gathered from the Gene Expression Omnibus
(GEO) service [57] using the Tuxedo suite, which employs
Bowtie [58], Cufflinks [59] and TopHat [60], to map the
sequence reads to the human genome (hg19 assembly)
and to evaluate the normalized expression of the Ensembl
splicing variants reported in Fragments Per Kilobase of
transcript per Million mapped reads (FPKM).
Description of additional data files
The following additional data files are available with the
online version of this paper. Additional files 1 and 2 are
tables listing, respectively, all the heterodimeric semi-
interfaces and the homodimeric interfaces we analyzed,
along with the alternative isoforms and the number of
interface residues they lack. The Additional file 3 is a set
of tables summarizing the results for single-isoform and
all-isoforms tests performed on both heterodimeric and
homodimeric entire binding sites. The Additional file 4 is a
set of tables summarizing the results of single-isoform and
all-isoforms tests performed on the hot spot residues of
heterodimeric binding sites. Additional files 5 and 6 are
tables listing all the transcripts that selectively lack hete-
rodimeric and homodimeric binding sites, respectively.
Additional files
Additional file 1: AS of heterodimeric interfaces. This table lists, for
each PDB chain involved in a heterodimeric interaction, the chain name
of its partner, the corresponding UniProt Accession Number and ENSTs,
the ENSTs of the alternative isoforms with identical coding sequence,
along with the fraction of interface and hot spot residues missing in
those isoforms.
Additional file 2: AS of homodimeric interfaces. This table lists, for
each pair of PDB chains involved in a homodimeric interaction, the
corresponding UniProt Accession Number and ENSTs, the ENSTs of the
alternative isoforms with identical coding sequence, along with the
fraction of interface residues of both chains missing in those isoforms.
Additional file 3: Single-isoform and all-isoforms tests results for
heterodimeric and homodimeric interfaces. This files include all the
tables summarizing the results of single-isoform and all-isoforms tests
performed on heterodimeric and homodimeric interfaces. The results of
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the tests performed only with isoforms whose sequences cover at least a
certain fraction of the canonical ones are also reported. Threshold is the
interface-removal threshold value used in the test. Spliced in real AS/Not
spliced in real AS is the number of isoforms that remove or not a
binding site (in the single-isoform test) or of binding sites that are
removed or not in one or more isoforms (in the all-isoforms test). Spliced
in random AS/Not spliced in random AS is the number of decoy isoforms
that remove or not a binding site (in the single-isoform test) or of
binding sites that are removed or not in one or more decoy isoforms
(in the all-isoforms test). Spliced in real AS fraction is the second column/
(second column + fourth column) fraction. While Spliced in random AS
fraction is the third column/ (third column + fifth column) fraction.
P-value is the p-value obtained for the CMH test.
Additional file 4: Single-isoform and all-isoforms tests results for
heterodimeric interfaces hot spots. This file includes all the tables
summarizing the results of single-isoform and all-isoforms tests
performed on the hot spot residues of heterodimeric binding sites. See
the legend of Additional file 3 for a description of the columns.
Additional file 5: Selectively spliced heterodimeric semi-interfaces.
This table lists the ENSTs of all the transcripts that selectively remove a
heterodimeric semi-interface.
Additional file 6: Selectively spliced homodimeric interfaces. This
table lists the ENSTs of all the transcripts that selectively remove a
homodimeric interface.
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